Tango Therapeutics, Inc.
Every calculator, already run for TNGX
Open the full toolkit →You have the numbers on TNGX. Get the argument.
A written report on which of these readings actually decide the outcome for Tango Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering TNGXAnalyst Price Target Disagreement for Tango Therapeutics, Inc.
Wall Street's bull case implies +185% from the current price; the bear case implies -1%. A 186% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TNGX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017…
TNGX — frequently asked
Is TNGX a buy right now?
Wall Street's consensus rating on Tango Therapeutics, Inc. is Strong Buy across 12 analysts, with a mean price target of $45.18 (+87% vs. the current $24.17). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is TNGX's next earnings date?
Tango Therapeutics, Inc. is next scheduled to report earnings around Nov 4, 2026. A full TNGX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Tango Therapeutics, Inc.?
Analysts covering Tango Therapeutics, Inc. (TNGX) range from a bear-case target of $24.00 to a bull-case high of $69.00, with a mean consensus target of $45.18 across 11 analysts. The spread of $45.00 (186% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Tango Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Tango Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TNGX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Tango Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.